BACKGROUND: In several malignant tissues, the angiopoietins are principal regulators of vascular growth and regression, but in normal prostate and prostate tumors the role of the angiopoietins is unknown. METHODS: Angiopoietin (ang) 1 and 2 were immunolocalized in TUR-diagnosed prostate tumors with long follow-up and the expression was related to vascular density and clinicopathological variables. RESULTS: Ang 1 was strongly expressed in the basal epithelial cell layer in non-malignant tissue, whereas tumors had lower levels localized to the epithelial cells. A weak ang 2 immunoreaction was observed in non-malignant tissue and in low to intermediate Gleason score (GS) tumors, with a similar expression pattern. However, most high GS tumors showed an intense ang 2 staining. Ang 2 was significantly correlated to GS, density of endoglin stained blood vessels, metastases, and to cancer specific survival. CONCLUSIONS: We conclude that ang 2 probably is an important regulator of angiogenesis in prostate cancer. (c) 2004 Wiley-Liss, Inc.
BACKGROUND: In several malignant tissues, the angiopoietins are principal regulators of vascular growth and regression, but in normal prostate and prostate tumors the role of the angiopoietins is unknown. METHODS:Angiopoietin (ang) 1 and 2 were immunolocalized in TUR-diagnosed prostate tumors with long follow-up and the expression was related to vascular density and clinicopathological variables. RESULTS:Ang 1 was strongly expressed in the basal epithelial cell layer in non-malignant tissue, whereas tumors had lower levels localized to the epithelial cells. A weak ang 2 immunoreaction was observed in non-malignant tissue and in low to intermediate Gleason score (GS) tumors, with a similar expression pattern. However, most high GS tumors showed an intense ang 2 staining. Ang 2 was significantly correlated to GS, density of endoglin stained blood vessels, metastases, and to cancer specific survival. CONCLUSIONS: We conclude that ang 2 probably is an important regulator of angiogenesis in prostate cancer. (c) 2004 Wiley-Liss, Inc.
Authors: Ajay P Singh; Sangeeta Bafna; Kunal Chaudhary; Ganesh Venkatraman; Lynette Smith; James D Eudy; Sonny L Johansson; Ming-Fong Lin; Surinder K Batra Journal: Cancer Lett Date: 2007-10-30 Impact factor: 8.679
Authors: K Danza; B Pilato; R Lacalamita; T Addati; F Giotta; A Bruno; A Paradiso; S Tommasi Journal: Eur J Hum Genet Date: 2012-12-12 Impact factor: 4.246
Authors: Colm Morrissey; Alex Dowell; Theodore D Koreckij; Holly Nguyen; Bryce Lakely; William C Fanslow; Lawrence D True; Eva Corey; Robert L Vessella Journal: Prostate Date: 2010-12-01 Impact factor: 4.104
Authors: Colm Morrissey; Lawrence D True; Martine P Roudier; Ilsa M Coleman; Sarah Hawley; Peter S Nelson; Roger Coleman; Ya-Chun Wang; Eva Corey; Paul H Lange; Celestia S Higano; Robert L Vessella Journal: Clin Exp Metastasis Date: 2007-10-31 Impact factor: 5.150